Results 251 to 260 of about 95,190 (307)

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

Has early mortality following single‐unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan

British Journal of Haematology, EarlyView.
The 100‐day non‐relapse mortality after single‐unit cord blood transplantation significantly declined from 19.6% (2003–2007) to 9.5% (2018–2022), while the 3‐year overall survival improved from 38.8% to 54.4%. Haematopoietic recovery rates improved steadily, with neutrophil engraftment reaching 89.6% and platelet engraftment 78.0% in the most recent ...
Takaaki Konuma, Junya Kanda, Naoyuki Uchida, Masatsugu Tanaka, Fumihiko Kimura, Hideki Nakasone, Yasufumi Uehara, Masahito Tokunaga, Masako Toyosaki, Shigesaburo Miyakoshi, Noriko Doki, Kazuya Ishiwata, Hikaru Kobayashi, Yasushi Onishi, Yasuji Kozai, Koji Kato, Fumihiko Ishimaru, Takahiro Fukuda, Yoshiko Atsuta, Satoshi Takahashi   +19 more
wiley   +1 more source

<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study. [PDF]

EJHaem
Haméon C, Houot R, Gyan E, Vallet N, Lachot S, Ganard M, Herault O, De Guibert S, Pastoret C, Dartigeas C.   +9 more
europepmc   +1 more source

European‐based polygenic risk score and genome‐wide association study of B‐cell non‐Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs

British Journal of Haematology, EarlyView.
Summary Among individuals of European Ancestry (EA), genome‐wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) and polygenic risk scores (PRSs) associated with non‐Hodgkin lymphoma (NHL) risk. We evaluated subtype‐specific PRSs, based on established EA‐SNPs, in Israeli Jews (IJ) and Palestinian Arabs (PA) and ...
Geffen Kleinstern, Dennis P. Robinson, Rania Abu Seir, Riki Perlman, Jianjun Liu, Nidal Jebrini, Hussein Elyan, Dina Ben Yehuda, Susan L. Slager, Ora Paltiel   +9 more
wiley   +1 more source

Expression of ADAM10 and CD58 in Acute and Chronic Lymphocytic Leukemia: Influence of Disease Stage and Chemotherapy. [PDF]

Iran J Pathol
Kadhim AH, Mohsin MI.
europepmc   +1 more source

Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Summary Ibrutinib is metabolized by cytochrome P450 3A (CYP3A) and poses challenges with drug interactions. We conducted a population‐based cohort study of Ontario residents aged ≥66 years who initiated ibrutinib for chronic lymphocytic leukaemia (CLL) to evaluate the frequency of potential drug interactions involving moderate/strong CYP3A inhibitors ...
Tuan Hoang, Matthew C. Cheung, David N. Juurlink, Kelvin K. W. Chan, Cindy Lau, Ning Liu, Husam Abdel‐Qadir, Anca Prica, Annette E. Hay, Abi Vijenthira, Lee Mozessohn   +10 more
wiley   +1 more source

Composite chronic lymphocytic leukemia and mantle cell lymphoma involving the bone marrow: a case report and literature review. [PDF]

J Pathol Transl Med
Demianets R, O'Brien S, Mahdavi K, Niu C, Aslam S, Tran T, Zhang Y, Gamayo A, Zhao X, Rezk SA.   +9 more
europepmc   +1 more source

Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party

British Journal of Haematology, EarlyView.
We retrospectively evaluated outcomes after a second haematopoietic stem cell transplantation (HSCT) performed between 2000 and 2022 for relapsed acute myeloid leukaemia in 345 children. We found that leukaemia‐free survival, overall survival, graft‐versus‐host disease (GVHD)/relapse‐free survival (GRFS) and relapse incidence improved over time, while ...
Nimrod Buchbinder, Victor Michel, Arnaud Dalissier, Katharina Kleinschmidt, Franco Locatelli, Alexei Maschan, Robert Wynn, Franca Fagioli, Marco Zecca, Charlotte Jubert, Birgitta Versluys, Petr Sedlacek, Ludmila Zubarovskaya, Marta Gonzalez Vicent, Alessandra Biffi, Gérard Michel, Oana Mirci‐Danicar, Wolfgang Holter, Marc Ansari, Jacques‐Emmanuel Galimard, Pascale Schneider, Mouad Abouqateb, Krzysztof Kałwak   +22 more
wiley   +1 more source

Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome. [PDF]

Ann Hematol
Cardinali V, Coiro S, Martelli MP, Sportoletti P.   +3 more
europepmc   +1 more source

The BH3‐only protein NOXA is essential for apoptosis induction by BH3‐mimetics targeting BCL2 or BCL‐XL in DLBCL

British Journal of Haematology, EarlyView.
Summary BCL2 inhibitors (BCL2i) have transformed the management of chronic lymphocytic leukaemia (CLL), but their use in more aggressive B‐cell malignancies such as diffuse large B‐Cell lymphoma (DLBCL) is complicated by the more heterogeneous nature of the disease.
Nahide Yildirim, Marius Anders, Victoria M. Smith, Sandrine Jayne, Moritz Assmann, Rebekah Jukes‐Jones, Martin J. S. Dyer, Meike Vogler   +7 more
wiley   +1 more source